AO "ranbaxy" Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: AO "ranbaxy" Pharmaceutical Import Records from India — 12 Products, $33.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AO "ranbaxy" — Pharmaceutical Importer Profile (2026) | 12 Products, $33.4M Trade | TransData Nexus

AO "ranbaxy"

Pharmaceutical Importer · Russia · Medical Devices & Diagnostics Focus · $33.4M Total Trade · DGFT Verified

AO "ranbaxy" is a pharmaceutical importer based in Russia with a total trade value of $33.4M across 12 products in 8 therapeutic categories. Based on 673 verified import shipments from Indian Customs (DGFT) records, AO "ranbaxy" is the #1 buyer in 3 products including Strip, Herbal, Norfloxacin. AO "ranbaxy" sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

AO "ranbaxy" — Import Portfolio & Supplier Network

AO "ranbaxy" import network — 12 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AO "ranbaxy"?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$26.9M	607	100.0%

AO "ranbaxy" sources from 1 verified Indian supplier across 362 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Ketanov tablets 10MG Pack:box20s	$987.9K	21
Coldact flu plus capsule Pack:10s	$800.0K	16
Sotret capsules 20MG Pack:box3x10s	$700.0K	14
Encorate chrono 500 tablets Pack:03*10	$650.0K	13
Encorate chrono 300MG tablets (sodium	$473.9K	11
Neotravisil herbal lozenges mint	$465.3K	10
Neotravisil herbal lozenges	$431.7K	9
Encorate chrono 500 tablets (sodium	$400.0K	8
Alfuprost mr TAB 10MG Pack:box3x10s	$400.0K	8
Ketanov tablets 10MG Pack:box10x10s	$394.0K	9
Neotravisil herbal lozenges lemon	$350.0K	7
Encorate 300 MG tablets (sodium	$338.2K	8
Niaspam 200MG capsules(mebeverine	$300.0K	6
Delsia tablets(drospirenone & ethinyl	$300.0K	6
Cifran ct TAB Pack: 10s strip batch	$300.0K	6

Import Portfolio — Top 12 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Strip	Medical Devices & Diagnostics	$15.4M	309	4.9%	1
2	Ciprofloxacin	Antibiotics	$5.0M	100	1.4%	7
3	Ketorolac	Analgesics & Antipyretics	$4.5M	90	1.5%	2
4	Herbal	Ayurvedic & Herbal Products	$2.1M	42	11.1%	1
5	Mesalamine	Gastrointestinal	$1.8M	36	0.1%	8
6	Ofloxacin	Advanced Antibiotics	$1.4M	28	0.5%	15
7	Norfloxacin	Advanced Antibiotics	$884.0K	22	8.5%	1
8	Kit	Medical Devices & Diagnostics	$600.0K	12	0.1%	11
9	Tinidazole	Advanced Antibiotics	$550.0K	11	1.9%	3
10	Fexofenadine	Antihistamines & Allergy	$500.0K	10	0.5%	17
11	Paracetamol	Analgesics & Antipyretics	$450.0K	9	0.1%	14
12	Ambroxol	Respiratory & OTC	$124.9K	4	0.8%	16

AO "ranbaxy" imports 12 pharmaceutical products across 8 categories into Russia totaling $33.4M. The company is the #1 buyer for 3 products: Strip, Herbal, Norfloxacin.

AO "ranbaxy" — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AO "Ranbaxy" is a prominent pharmaceutical importer and distributor based in Moscow, Russia. Established in 1993, the company has played a significant role in introducing and distributing pharmaceutical products within the Russian market. Over the years, AO "Ranbaxy" has developed a robust portfolio encompassing various therapeutic categories, including anti-infectives, pain management, cardiovascular, and dermatology. The company's strategic focus on high-quality, affordable medicines has enabled it to build strong relationships with healthcare providers and patients across Russia.

In 2015, following the global acquisition of Ranbaxy Laboratories by Sun Pharmaceutical Industries, AO "Ranbaxy" integrated into the Sun Pharma structure. This integration has further strengthened its position in the Russian pharmaceutical market, leveraging Sun Pharma's extensive resources and expertise. Today, AO "Ranbaxy" operates in 56 regions of Russia, offering a diverse range of pharmaceutical products that cater to the evolving healthcare needs of the population.

2Distribution Network

AO "Ranbaxy" maintains a comprehensive distribution network across Russia, ensuring the efficient delivery of pharmaceutical products to various regions. While specific warehouse locations are not publicly disclosed, the company's operations span 56 regions, indicating a well-established logistical framework capable of meeting the demands of the Russian market. This extensive coverage allows AO "Ranbaxy" to serve a wide customer base, including hospitals, clinics, pharmacies, and other healthcare facilities.

3Industry Role

In Russia's pharmaceutical supply chain, AO "Ranbaxy" functions primarily as a wholesaler and distributor. The company imports finished pharmaceutical formulations from manufacturers, particularly from India, and supplies these products to various stakeholders within the healthcare sector. By acting as an intermediary between international manufacturers and the Russian market, AO "Ranbaxy" plays a crucial role in ensuring the availability of a diverse range of pharmaceutical products to meet the needs of healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AO "ranbaxy"

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AO "Ranbaxy" demonstrates a high level of sourcing concentration, with a total import value of $33.4 million USD from India over 673 shipments, covering 12 products across 8 therapeutic categories. Notably, the company imports 86.5% of its products from a single supplier, Sun Pharmaceutical Industries Limited, indicating a strong and stable relationship. This concentrated sourcing strategy may offer benefits such as favorable pricing and consistent product quality. However, it also presents potential risks, including supply chain disruptions if the primary supplier faces operational challenges.

2Supply Chain Resilience

The resilience of AO "Ranbaxy"'s supply chain is closely tied to its reliance on Sun Pharmaceutical Industries Limited as the sole supplier. While this partnership offers stability and consistency, it also means that any disruptions at Sun Pharma could significantly impact AO "Ranbaxy"'s operations. The company imports a diverse range of formulations, encompassing 362 unique products, which may provide some buffer against supply chain disruptions. However, the lack of alternative suppliers for these products suggests limited flexibility in sourcing. To enhance supply chain resilience, AO "Ranbaxy" might consider diversifying its supplier base and establishing contingency plans to mitigate potential risks.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

In Russia, the circulation of medicinal products is regulated by the Federal Service on Surveillance in Healthcare, known as Roszdravnadzor. The primary legislation governing pharmaceutical imports is Federal Law No. 61-FZ, "On the Circulation of Medicinal Products," which outlines the procedures for importing, distributing, and marketing pharmaceutical products within the country. This law ensures that all medicinal products meet the required safety, efficacy, and quality standards before entering the Russian market.

2Import Licensing & GMP

Importing medicinal products into Russia requires compliance with specific licensing procedures. The process involves obtaining permits from Roszdravnadzor, followed by licenses issued by the Ministry of Industry and Trade. Additionally, imported pharmaceutical products must adhere to Good Manufacturing Practice (GMP) standards recognized by the European Union, World Health Organization, or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that the manufacturing processes meet international quality standards, which is crucial for the safety and efficacy of the products.

3Quality & Labeling

AO "ranbaxy" — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AO "Ranbaxy" focuses on importing a diverse range of pharmaceutical products across multiple therapeutic categories, including anti-infectives, pain management, cardiovascular, and dermatology. This strategic approach allows the company to address a wide array of healthcare needs within the Russian market. The demand for these products is driven by the prevalence of various health conditions and the need for effective treatments. By offering a comprehensive product portfolio, AO "Ranbaxy" aims to provide accessible and affordable healthcare solutions to the Russian population.

2Sourcing Profile

AO "Ranbaxy" primarily sources generic pharmaceutical formulations from India, with Sun Pharmaceutical Industries Limited being its sole supplier. This sourcing strategy emphasizes the procurement of high-quality, cost-effective products to meet the diverse needs of the Russian market. The focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that can be directly distributed to healthcare providers and patients.

3Market Positioning

Seller's Guide — How to Become a Supplier to AO "ranbaxy"

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Russian market and collaborate with AO "Ranbaxy". By offering competitive pricing, consistent product quality, and reliable delivery, new suppliers can position themselves as viable alternatives to Sun Pharmaceutical Industries Limited. This diversification can enhance AO "Ranbaxy"'s supply chain resilience and provide Russian consumers with a broader range of pharmaceutical products. Identifying gaps in AO "Ranbaxy"'s current sourcing, such as specific therapeutic areas or product forms, can further inform strategic sourcing decisions.

2Requirements & Qualifications

Indian exporters seeking to supply AO "Ranbaxy" and the Russian market must ensure that their products comply with Russian regulatory standards. This includes obtaining GMP certifications recognized by the European Union, World Health Organization, or PIC/S. Additionally, products must meet Russian labeling requirements, including Russian language labeling and adherence to serialization mandates. Import licensing procedures must be followed, involving permits from Roszdravnadzor and licenses from the Ministry of Industry and Trade. Ensuring compliance with these standards is essential for successful market entry and distribution within Russia.

Frequently Asked Questions — AO "ranbaxy"

What products does AO "ranbaxy" import from India?

AO "ranbaxy" imports 12 pharmaceutical products across 8 categories. Top imports: Strip ($15.4M), Ciprofloxacin ($5.0M), Ketorolac ($4.5M), Herbal ($2.1M), Mesalamine ($1.8M).

Who supplies pharmaceuticals to AO "ranbaxy" from India?

AO "ranbaxy" sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $26.9M).

What is AO "ranbaxy"'s total pharmaceutical import value?

AO "ranbaxy"'s total pharmaceutical import value from India is $33.4M, based on 673 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AO "ranbaxy" focus on?

AO "ranbaxy" imports across 8 categories. The largest: Medical Devices & Diagnostics (48.1%), Antibiotics (15.0%), Analgesics & Antipyretics (14.8%).

Get Full AO "ranbaxy" Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.